OrganDots - An organotypic 3D tissue culture platform for drug development

Expert Opinion on Drug Discovery

Volumn 7, Issue 6, 2012, Pages 525-534

  Sundstrom, Lars ^a,b   Biggs, Thelma ^b   Laskowski, Alexandra ^b   Stoppini, Luc ^b,c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b Capsant Ltd   (United Kingdom)

^c HEPIA   (Switzerland)

Author keywords

3D tissue culture; Drug testing; Organotypic; Stem cells

Indexed keywords

ARTICLE; CELL AGGREGATION; CENTRIFUGATION; DRUG DEVELOPMENT; DRUG SAFETY; DRUG SCREENING; EX VIVO STUDY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICROELECTRODE; NONHUMAN; ORGANDOTS; PRIORITY JOURNAL; SPHEROID CELL; STEM CELL; TISSUE CULTURE; TISSUE ENGINEERING;

ANIMALS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; STEM CELLS; TISSUE CULTURE TECHNIQUES;

EID: 84861510668     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2012.686488     Document Type: Article

References (56)

1. Picard S, Goineau S, Guillaume P, et al. Supplemental studies for cardiovascular risk assessment in safety pharmacology: a critical overview. Cardiovasc Toxicol 2011;11:285-307
2. Sundstrom LE. Thinking inside the box: to cope with an increasing disease burden, drug discovery needs biologically relevant and predictive testing systems. EMBO Rep 2007;8:40-3
3. Walker MJ, Barrett T, Guppy LJ. Functional pharmacology: the drug discovery bottleneck? Drug Discov Today Targets 2004;3:208-15 . Describes the limitations of current methods for secondary drug screening.
4. Carrel A, Burrow MT. Cultivation of tissues in vitro and its technique. J Exp Med 1911;13:387-96
5. Harrison R. Observations on the living developing nerve fiber. Anat Rec 1907;1:116-28
6. Carrel A. On the permanent life of tissues outside of the organism. J Exp Med 1912;15:516-28
7. Groneberg DA, Grosse-Siestrup C, Fischer A. In vitro models to study hepatotoxicity. Toxicol Pathol 2002;30(3):394-9
8. Picard S, Lacroix P. QT interval prolongation and cardiac risk assessment for novel drugs. Curr Opin Investig Drugs 2003;4(3):303-8
9. Li CL, McIlwain H. Maintenance of resting membrane potentials in slices of mammalian cerebral cortex and other tissues in vitro. J Physiol 1957;139(2):178-90
10. Gahwiler BH, Capogna M, Debanne D, et al. Organotypic slice cultures: a technique has come of age. Trends Neurosci 1997;20(10):471-7. Review
11. Stoppini L, Buchs PA, Muller D. A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 1991;37(2):173-82
12. Sundstrom L, Morrison B III, Bradley M, et al. Organotypic cultures as tools for functional screening in the CNS. Drug Discov Today 2005;10(14):993-1000
13. Ridky TW, Chow JM, Wong DJ, et al. Invasive three-dimensional organotypic neoplasia from multiple normal human epithelia. Nat Med 2010;16(12):1450-5
14. Mueller-Klieser W. Multicellular spheroids. A review on cellular aggregates in cancer research. 1987;113(2):101-22
15. Honegger P. Aggregate cell cultures ALTEX 1987;6(1):29-36
16. Mironov V, Bolans T, Trusk T, et al. Organ printing: computer aided Jet-based 3D tissue engineering. Trends Biotechnol 2003;4:157-61
17. Mehesz AN, Brown J, Hajdu Z, et al. Scalable robotic biofabrication of tissue spheroids. Biofabrication 2011;3(2): doi:10.1088/1758-5082/3/2/ 025002
18. Drewitz M, Helbling M, Fried N, et al. Towards automated production and drug sensitivity testing using scaffold-free spherical tumor microtissues. Biotechnol J 2011;6(12):1488-96
19. Tung YC, Hsiao AY, Allen SG, et al. High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array. Analyst 2011;136(3):473-8
20. Portner R, Giese C. An overview of bioreactor design prototyping and process control for reproducible three-dimensional tissue culture. In: Marx S, Sandig V, editors. Drug Testing In Vitro, Breakthroughs and Trends in Cell Culture Technology. Wiley ISBN978-3-527-31488-1, Hoboken, New Jersey, 2007
21. Justice BA, Badr NA, Felder RA. 3D cell culture opens new dimensions in cell-based assays. Drug Discov Today 2009;14(1-2):102-7
22. Derda R, Laromaine A, Mammoto A, et al. Paper-supported 3D cell culture for tissue-based bioassays. PNAS 2009;106(44):18457-62
23. Stoppini L, Cater H, Bonfante R, et al. Organotypic in-vitro systems for compound testing for CNS disorders. Conference Proceedings of the 5th International Meeting on Substrate-Integrated Micro Electrode Arrays; 4 - 7 July 2006. p. 99-100
24. Bailey J, O'Connor V, Hannah M, et al. In vitro CNS tissue analogues formed by self-organisation of reaggregated post-natal brain tissue. J Neurochem 2011;117(6):1020-32
25. Domansky K, Inman W, Serdy J, et al. Perfused multiwell plate for 3D liver tissue engineering. Lab Chip 2010;10(1):51-8
26. Martin I, Wendt D, Heberer M. The role of bioreactors in tissue engineering. Trends Biotechnol 2004;22(2):80-6
27. Urciuolo F, Imparato G, Guaccio A, et al. Novel strategies to engineering biological tissue in vitro. Methods Mol Biol 2012;811:223-44
28. Stelzer EH. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 2007;8(10):839-45
29. Ringeisen BR, Othon CM, Barron JA, et al. Jet-based methods to print living cells. Biotechnol J 2006;1(9):930-48
30. Guillotin B, Guillemot F. Cell patterning technologies for organotypic tissue fabrication. Trends Biotechnol 2011;29(4):183-90
31. Xu F, Celli J, Rizvi I, et al. A three-dimensional in vitro ovarian cancer coculture model using a high-throughput cell patterning platform. Biotechnol J 2011;6(2):204-12
32. Layer PG, Robitzki A, Rothermel A, et al. Of layers and spheres: the reaggregate approach in tissue engineering. Trends Neurosci 2002;25(3):131-4
33. Reininger-Mack A, Thielecke H, Robitzki AA. 3D-biohybrid systems: applications in drug screening. Trends Biotechnol 2002;20(2):56-61
34. Roguet R, Regnier M, Cohen C, et al. The use of in vitro reconstituted human skin in dermotoxicity testing. Toxicol In Vitro 1994;8(4):635-9
35. Gangatirkar P, Paquet-Fifield S, Li A, et al. Establishment of 3D organotypic cultures using human neonatal epidermal cells. Nat Protoc 2007;2(1):178-86
36. Berube K, Pitt A, Hayden P, et al. Filter-well technology for advanced three-dimensional cell culture: perspectives for respiratory research. Altern Lab Anim 2010;38(Suppl 1):49-65
37. van Vliet E, Stoppini L, Balestrino M, et al. Electrophysiological recording of re-aggregating brain cell cultures on multi-electrode arrays to detect acute neurotoxic effects. Neurotoxicology 2007;28(6):1136-46
38. Noraberg J, Gramsbergen JB, Fonnum F, et al. Trimethyltin (TMT) neurotoxicity in organotypic rat hippocampal slice cultures. Brain Res 1998;783(2):305-15
39. Noraberg J. Organotypic brain slice cultures: an efficient and reliable method for neurotoxicological screening and mechanistic studies. Altern Lab Anim 2004;32(4):329-37
40. Biggs T, Foreman J, Sundstrom L, et al. Antitumor compound testing in glioblastoma organotypic brain cultures. J Biomol Screen 2011;16(8):805-17
41. Benbrook DM. Organotypic cultures represent tumour microenvironment for drug testing. Drug Discov Today 2006;2:143-8
42. Yamada K, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007;130:601-10
43. Malanchi I, Santamaria-Martinez A, Susanto E, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2011;481(7379):85-9
44. Kimlin LC, Casagrande G, Virador VM. In vitro three-dimensional (3D) models in cancer research: an update. Mol Carcinog 2011. [Epub ahead of print]
45. Martin KJ, Patrick DR, Bissell MJ, et al. Prognostic breast cancer signature Identified from 3D culture Model accurately predicts clinical outcome across multiple independent datasets. PLoS ONE 2008;8:e2994
46. Dubois-Dauphin ML, Toni N, Julien SD, et al. The long-term survival of in vitro engineered nervous tissue derived from the specific neural differentiation of mouse embryonic stem cells. Biomaterials 2010;27:7032-42
47. Preynat-Seauve O, Suter DM, Tirefort D, et al. Development of human nervous tissue upon differentiation of embryonic stem cells in three-dimensional culture. Stem Cells 2009;27(3):509-20
48. Inoue H, Yamanaka S. The use of induced pluripotent stem cells in drug development. Clin Pharmacol Ther 2011;89(5):655-61
49. Ebert AD, Yu J, Rose FF Jr, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009;457(7227):277-80
50. Brennand KJ, Simone A, Jou J, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011;473(7346):221-5
51. Tobe BT, Snyder EY, Nye JS. Modeling complex neuropsychiatric disorders with human induced pluripotent stem cells. Curr Opin Pharmacol 2011;11(5):521-7
52. Josowitz R, Carvajal-Vergara X, Lemischka IR, et al. Induced pluripotent stem cell-derived cardiomyocytes as models for genetic cardiovascular disorders. Curr Opin Cardiol 2011;26(3):223-9. Review
53. Lahti AL, Kujala VJ, Chapman H, et al. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech 2012; 2:220-30; doi:10.1242/ dmm.008409
54. Editorial 'Goodbye, flat biology? Nature 2003;424:861
55. Pampaloni F, Reynaud EG, Stelzer EH. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 2007;8(10):839-45
56. Marx U. How drug development of the 21st century could benefit from human micro-organoid in-vitro technologies. In: Marx S, Sandig V, editors. Drug Testing In Vitro: Breakthroughs and Trends in Cell Culture Technology, Wiley ISBN978-3-527-31488-1, Hoboken, New Jersey, 2007. p. 271-83